LINK Strengthens Presence in Switzerland with Distribution Agreement
News Sep 04, 2015
LINK has announced the appointment of a new distributor in Switzerland - Chemie Brunschwig AG. This is LINK's first formal partnership in Europe, and an important part of its strategy to strengthen Company representation in important market segments, thus increasing access to LINK's range of innovative reagents for oligo therapeutics and diagnostics.
Chemie Brunschwig AG distributes over one million different chemicals, life science products and lab-ware to laboratories ranging from research and development to production in the Swiss market. Founded in 1948, the company has developed a wide R&D user base across industry, hospitals, private and public health labs, research centres, and universities. Located in Basle, on the border to Germany and France in the Bio Valley, staff are able to communicate with customers in all three regional languages.
Emmanuel Picard, Marketing & Sales Manager for Chemie Brunschwig, commented: "We are delighted to agree this partnership with LINK. It is an exciting opportunity to expand our portfolio of products, whilst playing a key role in driving LINK's growth in the region."
Dr David Ricketts, CEO of LINK, added: "In our home market of Europe, there are certain geographical areas where our customers can benefit from increased local representation due to factors such as language and purchasing regulations. It is essential therefore that we give these customers such a service. We have already developed a successful working relationship with Chemie Brunschwig, driving growth in Switzerland, and formally appointing them as our distributor was the next logical step. They are a company very much aligned to our ethos of quality and service, and we look forward to working with them to take our business forward."
Patients in a new Northwestern Medicine study were able to comprehend words that were written but not said aloud. They could write the names of things they saw but not verbalize them. This provides an insight into the brain degeneration that defines the rare dementia termed primary progressive aphasia.
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE